New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, Inc.
Explore this paper's citation graph
Summary
Royalty Pharma is the largest of these drug royalty investment companies, and in this case study, it is shown how its unique financing structure greatly enhances the impact it has had on the biopharma industry and biomedical innovation.
- Type
- article
- Published
- 2013-12-15
- Cited by
- 22
- References
- 19
- Access
- Open access
- OpenAlex
- https://openalex.org/W16746540
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5661325
Keywords
Business, Finance
References
- Rebuilding the R&D engine in big pharma.
- The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001
- Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
- Pharmaceutical patents and price controls.
- The future of research funding in academic medicine.
- Biotechs follow big pharma lead back into academia
- Commercializing biomedical research through securitization techniques
- Deal watch: Trends in discovery externalization
- Pharmaceuticals in U.S. health care: determinants of quantity and price.
- Drug discovery: new models for industry-academic partnerships.
- The price of innovation: new estimates of drug development costs.
- Can Financial Engineering Cure Cancer
- How to improve R&D productivity: the pharmaceutical industry's grand challenge
- Louis G. Baldwin - Executive Vice President and Chief Financial Officer
Cited by
- Adaptive design of clinical trials : understanding the barriers to adoption
- Parallel Discovery of Alzheimer’s Therapeutics
- Financing translation: Analysis of the NCATS rare-diseases portfolio
- Analytics for financing drug development
- Financing drug discovery via dynamic leverage.
- Funding Translational Medicine via Public Markets: The Business Development Company
- Balancing Risk and Learning Opportunities in Corporate Venture Capital Investments: Evidence from the Biopharmaceutical Industry
- Early Stage Biopharmaceutical R&D Financing: A Real Options Approach
- Hedging Longevity Risk in Life Settlements Using Biomedical Research‐Backed Obligations
- CONDITIONS OF INTEREST OF A LONGEVITY MEGAFUND FOR PENSION FUNDS
- New financing and business models to accelerate the development of novel therapeutics
- Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?
- Analyses prospectives de mortalité : approches actuarielle et biomédicale
- Venture Philanthropy: A Case Study of the Cystic Fibrosis Foundation
- Adaptability evolution of financing systems of mega projects
- Financially adaptive clinical trials via option pricing analysis
- Financing Biomedical Innovation
- Fuzzy causal model of enterprise flexibility dimensions using Fermatean Fuzzy DEMATEL: a case study of Indian pharmaceutical industry
- Financing drug development via adaptive platform trials
- feature Financing drug discovery via dynamic leverage
Related papers
- Halal Food Logistics: The Challenges among Food & Beverages Small and Medium Sizes Manufacturers
- Driving In-Role and Extra-Role Brand Performance among Retail Frontline Salespeople: Antecedents and the Moderating Role of Customer Orientation
- Determinant factors towards the adoption of halal logistics services among Malaysian halal Small Medium Enterprises (SMES)
- Managing brand portfolios: audit of leading grocery supplier brands 2004 to 2012
- Impact of halal supplier service quality and staff readiness to adopt halal technology on halal logistics performance: a study of Indonesian halal meat supply chain
- Small Producers and Retailers Network Supply Chains Integration
- The Effect of CSR Activities of Jeju Lodging Companies on Management Performance
- Sub‐contractor and customer sourcing and the occurrence of disturbances in firms’ inbound and outbound logistics flows
- Project Finance and Corporate Finance: Comparative Analysis as means of financing for infrastructure projects.